Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis
P. Canales-Herrerias, M. Uzzan, A. Seki, R. S. Czepielewski, B. Verstockt, A. Livanos, F. Raso, A. Dunn, D. Dai, A. Wang, Z. Al-taie, J. Martin, H. M. Ko, M. Tokuyama, M. Tankelevich, , S. Mehandru
This study investigates the mechanism of vedolizumab in ulcerative colitis by analyzing immune cell changes in gut-associated lymphoid tissue and shows that targeting GALT is a novel mechanism of action.
bioRxiv · Jan 19, 2023Immunology